Kohjin Bio Co., Ltd. (TYO:177A)
Japan · Delayed Price · Currency is JPY 1,202.00
-18.00 (-1.48%)
At close: Feb 6, 2026
Kohjin Bio Revenue
Kohjin Bio had revenue of 1.29B JPY in the quarter ending September 30, 2025, with 1.50% growth. This brings the company's revenue in the last twelve months to 5.20B. In the fiscal year ending March 31, 2025, Kohjin Bio had annual revenue of 5.21B with 9.14% growth.
Revenue (ttm)
5.20B
Revenue Growth
+9.14%
P/S Ratio
1.18
Revenue / Employee
31.16M
Employees
167
Market Cap
6.14B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 5.21B | 436.00M | 9.14% |
| Mar 31, 2024 | 4.77B | 28.00M | 0.59% |
| Mar 31, 2023 | 4.74B | 795.00M | 20.14% |
| Mar 31, 2022 | 3.95B | 809.83M | 25.81% |
| Mar 31, 2021 | 3.14B | 861.62M | 37.86% |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Transgenic Group | 12.92B |
| Linical | 9.87B |
| Soiken Holdings | 4.87B |
| OncoTherapy Science | 956.00M |
| Chiome Bioscience | 727.99M |
| PRISM BioLab Co.,LTD | 677.33M |
| Carna Biosciences | 544.45M |
| D. Western Therapeutics Institute | 419.76M |